What caused the large increase in GAAP net loss in Q4 2023?

The increase was primarily due to an $83.4 million non-recurring other operating expense related to a legal accrual. The company stated that excluding this item, loss from operations improved by $32.0 million year over year in Q4, and interest income rose $11.7 million. The release does not specify the nature of the legal matter, so investors should review the 10-K for details.

Why did gross margin decline in 2023?

Precision oncology gross margin fell modestly to 60% from 62%, mainly due to product mix. Development services and other gross margin dropped to 57% from 86%, reflecting the full-year cost of processing Shield LDT samples as part of screening market development, for which the company is currently booking minimal revenue.

What is the outlook for 2024 and what are the key risks?

Guidance calls for 2024 revenue excluding screening of $655–$670 million, non-GAAP gross margin excluding screening of 60%–62%, non-GAAP operating expenses of $740–$750 million, and free cash flow of negative $320–$330 million. Key risks include the timing and outcome of the FDA review of the Shield PMA, the Advisory Committee Panel, and the pace of Shield adoption following any approval, as described in the company's forward-looking statements.

What is the status of the Shield blood-based colorectal cancer screening test?

Guardant is continuing to work with the FDA on its PMA submission for Shield and anticipates an upcoming Advisory Committee Panel as the next review step. The company expects to launch the Shield IVD test broadly later in 2024 following expected FDA approval. Investors should note that FDA approval is not yet granted and the timing is uncertain.

How strong is the company's liquidity position?

Guardant ended 2023 with $1.2 billion in cash, cash equivalents and marketable debt securities, up from prior-year levels after shifting short-term marketable securities into cash. Free cash flow remained negative at $345.5 million for 2023, though it improved from $386.9 million in 2022, and the company guided to a further improvement to negative $320–$330 million in 2024.

GH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.

Guardant Health (GH) reported Q4 and full-year 2023 results on February 22, 2024, with full-year revenue of $563.9 million^a, up 25% year over year, driven by clinical test volume growth of 39%.

Precision oncology revenue grew 31% to $514.2 million^b, while development services and other revenue fell 14% to $49.7 million on lower companion diagnostic milestone timing and reduced royalties. Gross margin declined to 60% from 65%, mainly due to product mix and the cost of processing Shield LDT samples for which the company is booking minimal revenue. Free cash flow improved to negative $345.5 million from negative $386.9 million, and the company ended the year with $1.2 billion in cash, cash equivalents and marketable debt securities.

GAAP results were distorted by an $83.4 million^c non-recurring legal accrual recorded in Q4 2023, which pushed the full-year GAAP net loss to $479.4 million (or $4.28 per share), versus $654.6 million in 2022. Excluding the accrual and other non-GAAP adjustments, non-GAAP net loss was $352.3 million, or $3.15 per share, compared with $4.26 per share in 2022. Adjusted EBITDA loss narrowed to $344.2 million from $403.4 million.

Management noted that the Therapy Selection business reached cash flow breakeven by year-end 2023. Looking ahead, Guardant guided 2024 revenue (excluding screening) to $655^d–$670 million, implying 16%–19% growth, with non-GAAP gross margin excluding screening of 60%–62%, non-GAAP operating expenses of $740–$750 million, and free cash flow of negative $320–$330 million.

The company is awaiting FDA approval of its Shield blood-based colorectal cancer screening test, with an Advisory Committee Panel expected as the next step; the Shield IVD launch is planned for later in 2024 following approval. Investors should watch the FDA review outcome, the Guardant360 LDT reimbursement increase from $3,500 to $5,000 effective January 1, 2024, and whether the legal accrual represents a one-time charge.

02—Key points

Key Highlights

Full-year 2023 revenue rose 25% to $563.9 million, with clinical test volume up 39% to 172,900 tests and precision oncology revenue up 31% to $514.2 million.
Gross margin fell to 60% from 65%, driven by product mix in precision oncology and the cost of processing Shield LDT samples with minimal associated revenue.
An $83.4 million non-recurring legal accrual in Q4 2023 drove the GAAP net loss to $479.4 million ($4.28 per share), while non-GAAP net loss improved to $352.3 million ($3.15 per share) from $435.4 million.
Adjusted EBITDA loss narrowed to $344.2 million from $403.4 million, and free cash flow improved to negative $345.5 million from negative $386.9 million.
The company ended 2023 with $1.2 billion in cash, cash equivalents and marketable debt securities, and the Therapy Selection business reached cash flow breakeven by year-end.
2024 guidance calls for revenue excluding screening of $655–$670 million (16%–19% growth), non-GAAP operating expenses of $740–$750 million, and free cash flow of negative $320–$330 million.
Guardant360 LDT CMS reimbursement increased from $3,500 to $5,000 effective January 1, 2024, supporting future average selling prices; Shield's FDA PMA review is advancing toward an Advisory Committee Panel.

03—Questions

Frequently Asked Questions

What caused the large increase in GAAP net loss in Q4 2023?
The increase was primarily due to an $83.4 million non-recurring other operating expense related to a legal accrual. The company stated that excluding this item, loss from operations improved by $32.0 million year over year in Q4, and interest income rose $11.7 million. The release does not specify the nature of the legal matter, so investors should review the 10-K for details.
Why did gross margin decline in 2023?
Precision oncology gross margin fell modestly to 60% from 62%, mainly due to product mix. Development services and other gross margin dropped to 57% from 86%, reflecting the full-year cost of processing Shield LDT samples as part of screening market development, for which the company is currently booking minimal revenue.
What is the outlook for 2024 and what are the key risks?
Guidance calls for 2024 revenue excluding screening of $655–$670 million, non-GAAP gross margin excluding screening of 60%–62%, non-GAAP operating expenses of $740–$750 million, and free cash flow of negative $320–$330 million. Key risks include the timing and outcome of the FDA review of the Shield PMA, the Advisory Committee Panel, and the pace of Shield adoption following any approval, as described in the company's forward-looking statements.
What is the status of the Shield blood-based colorectal cancer screening test?
Guardant is continuing to work with the FDA on its PMA submission for Shield and anticipates an upcoming Advisory Committee Panel as the next review step. The company expects to launch the Shield IVD test broadly later in 2024 following expected FDA approval. Investors should note that FDA approval is not yet granted and the timing is uncertain.
How strong is the company's liquidity position?
Guardant ended 2023 with $1.2 billion in cash, cash equivalents and marketable debt securities, up from prior-year levels after shifting short-term marketable securities into cash. Free cash flow remained negative at $345.5 million for 2023, though it improved from $386.9 million in 2022, and the company guided to a further improvement to negative $320–$330 million in 2024.

04—Continue

← View all 8-K filings